Friday’s Midday Stock Update: Acura Pharmaceuticals (ACUR), IntelliPharmaCeutics International (IPCI), Anthera Pharmaceuticals (ANTH), CytRx Corporation (CYTR), Civeo Corp (CVEO)

By Carrie Williams

So far Friday, January 11, NASDAQ is up 0.04% and the S&P is up 0.68%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Acura Pharmaceuticals (ACURResearch Report), IntelliPharmaCeutics International (IPCIResearch Report), Anthera Pharmaceuticals (ANTHResearch Report), CytRx Corporation (CYTRResearch Report) and Civeo Corp (CVEOResearch Report).

Acura Pharmaceuticals is up 33.33% in midday trading to $0.15. Shares opened today at $0.11. The company has a 52-week low of $0.06 and a 52-week high of $0.00.

IntelliPharmaCeutics International is up 13.79% in midday trading to $0.33. Shares opened today at $0.29. The company has a 52-week low of $0.20 and a 52-week high of $0.00.

Anthera Pharmaceuticals is down -11.05% in midday trading to $0.06. Shares opened today at $0.07. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

CytRx Corporation is up 8.93% in midday trading to $0.60. Shares opened today at $0.55. The company has a 52-week low of $0.33 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.50, marking a 718.18% potential upside from current levels. In a report issued on January 4, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CYTR, with a price target of $4.50, which implies an upside of 718% from current levels.

See today’s analyst top recommended stocks >>

Civeo Corp is up 8.71% in midday trading to $2.19. Shares opened today at $2.01. The company has a 52-week low of $1.12 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.00, marking a 99.00% potential upside from current levels. In a report issued on October 31, Craig-Hallum analyst Mike Malouf maintained a Buy rating on CVEO, with a price target of $4, which implies an upside of 99% from current levels.

Trending Stocks Based on Insider Activity >>